癌症最新文献

{"title":"Predictive factors for the local recurrence and distant metastasis of phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center.","authors":"Jing Wei,&nbsp;Yu-Ting Tan,&nbsp;Yu-Cen Cai,&nbsp;Zhong-Yu Yuan,&nbsp;Dong Yang,&nbsp;Shu-Sen Wang,&nbsp;Rou-Jun Peng,&nbsp;Xiao-Yu Teng,&nbsp;Dong-Geng Liu,&nbsp;Yan-Xia Shi","doi":"10.5732/cjc.014.10048","DOIUrl":"https://doi.org/10.5732/cjc.014.10048","url":null,"abstract":"<p><p>The local recurrence rate of phyllodes tumors of the breast varies widely among different subtypes, and distant metastasis is associated with poor survival. This study aimed to identify factors that are predictive of local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) in patients with phyllodes tumors of the breast. Clinical data of all patients with a phyllodes tumor of the breast (n = 192) treated at Sun Yat-sen University Cancer Center between March 1997 and December 2012 were reviewed. The Pearson Χ² test was used to investigate the relationship between clinical features of patients and histotypes of tumors. Univariate and multivariate Cox regression analyses were performed to identify factors that are predictive of LRFS, DMFS, and OS. In total, 31 (16.1%) patients developed local recurrence, and 12 (6.3%) developed distant metastasis. For the patients who developed local recurrence, the median age at the diagnosis of primary tumor was 33 years (range, 17-56 years), and the median size of primary tumor was 6.0 cm (range, 0.8-18 cm). For patients who developed distant metastasis, the median age at the diagnosis of primary tumor was 46 years (range, 24-68 years), and the median size of primary tumor was 5.0 cm (range, 0.8-18 cm). In univariate analysis, age, size, hemorrhage, and margin status were found to be predictive factors for LRFS (P = 0.009, 0.024, 0.004, and 0.001, respectively), whereas histotype, epithelial hyperplasia, margin status, and local recurrence were predictors of DMFS (P = 0.001, 0.007, 0.007, and < 0.001, respectively). In multivariate analysis, independent prognostic factors for LRFS included age [hazard ratio (HR) = 3.045, P = 0.005], tumor size (HR = 2.668, P = 0.013), histotype (HR = 1.715, P = 0.017), and margin status (HR = 4.530, P< 0.001). Histotype (DMFS: HR = 4.409, P = 0.002; OS: HR = 4.194, P = 0.003) and margin status (DMFS: HR = 2.581, P = 0.013; OS: HR = 2.507, P = 0.020) were independent predictors of both DMFS and OS. In this cohort, younger age, a larger tumor size, a higher tumor grade, and positive margins were associated with lower rates of LRFS. Histotype and margin status were found to be independent predictors of DMFS and OS.</p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 10","pages":"492-500"},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5732/cjc.014.10048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32570057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel anti-melanoma treatment: focus on immunotherapy.","authors":"Meng-Ze Hao,&nbsp;Wen-Ya Zhou,&nbsp;Xiao-Ling Du,&nbsp;Ke-Xin Chen,&nbsp;Guo-Wen Wang,&nbsp;Yun Yang,&nbsp;Ji-Long Yang","doi":"10.5732/cjc.014.10118","DOIUrl":"https://doi.org/10.5732/cjc.014.10118","url":null,"abstract":"<p><p>Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"458-65"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/80/cjc-33-09-458.PMC4190435.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32641173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"James P. Allison received the 2014 Szent-Györgi Prize for Progress in Cancer Research.","authors":"Jie Zhao,&nbsp;Peter Scully,&nbsp;Sujuan Ba","doi":"10.5732/cjc.014.10125","DOIUrl":"https://doi.org/10.5732/cjc.014.10125","url":null,"abstract":"<p><p>The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National Foundation for Cancer Research (NFCR) -- a leading cancer research charitable organization in the United States that is committed to supporting innovative cancer research on the global scale that aims to cure cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher whose original discoveries have expanded our understanding of cancer and resulted in notable advances in cancer prevention, diagnosis, or treatment. The prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the history and mission of the Szent-Györgyi Prize, its role in promoting discovery-oriented cancer research, and the pioneering work led by the 2014 prize winner, Dr. James Allison. Dr. Allison's work in the area of cancer immunotherapy led to the successful development of immune checkpoint therapy, and the first drug approved by the United States Food and Drug Administration for the treatment of metastatic melanoma. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"416-20"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/49/cjc-33-09-416.PMC4190431.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32640714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors in clinical trials.","authors":"Elad Sharon, Howard Streicher, Priscila Goncalves, Helen X Chen","doi":"10.5732/cjc.014.10122","DOIUrl":"10.5732/cjc.014.10122","url":null,"abstract":"<p><p>Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called \"immune checkpoints.\" These checkpoints serve to control or turn off the immune response when it is no longer needed to prevent tissue injury and autoimmunity. Cancer cells have learned or evolved to use these mechanisms to evade immune control and elimination. The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, non-small cell lung cancer, and several other tumor types. Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clinical development. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"434-44"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/07/cjc-33-09-434.PMC4190433.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32640716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors.","authors":"Alan D Guerrero,&nbsp;Judy S Moyes,&nbsp;Laurence J N Cooper","doi":"10.5732/cjc.014.10100","DOIUrl":"https://doi.org/10.5732/cjc.014.10100","url":null,"abstract":"<p><p>The adoptive transfer of T cells is a promising approach to treat cancers. Primary human T cells can be modified using viral and non-viral vectors to promote the specific targeting of cancer cells via the introduction of exogenous T-cell receptors (TCRs) or chimeric antigen receptors (CARs). This gene transfer displays the potential to increase the specificity and potency of the anticancer response while decreasing the systemic adverse effects that arise from conventional treatments that target both cancerous and healthy cells. This review highlights the generation of clinical-grade T cells expressing CARs for immunotherapy, the use of these cells to target B-cell malignancies and, particularly, the first clinical trials deploying the Sleeping Beauty gene transfer system, which engineers T cells to target CD19+ leukemia and non-Hodgkin's lymphoma. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"421-33"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/2c/cjc-33-09-421.PMC4190432.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32640715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer immunotherapy.","authors":"Li Yan,&nbsp;Helen X Chen","doi":"10.5732/cjc.014.10153","DOIUrl":"https://doi.org/10.5732/cjc.014.10153","url":null,"abstract":"Authors′ Affiliations: US Chinese Anti-Cancer Association; Therapy Evaluation Program (CTEP) National Cancer Institute (NCI), Bethesda, MD 20892, USA. Corresponding Authors: Li Yan, US Chinese Anti-Cancer Association. Tel: +1-610-213-7025; Email: ynyinternational@yahoo.com. Helen X. Chen, Therapy Evaluation Program (CTEP) National Cancer Institute (NCI), 6130 Executive Blvd, EPN 7131, Bethesda, MD 20892, USA. Tel: +1-240-276-6106; Email: helen.chen@nih.gov. doi: 10.5732/cjc.014.10153 Li Yan and Helen X. Chen","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"413-5"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/70/cjc-33-09-413.PMC4190430.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32882726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer immunotherapy in clinical practice -- the past, present, and future.","authors":"Gaurav Goel,&nbsp;Weijing Sun","doi":"10.5732/cjc.014.10123","DOIUrl":"https://doi.org/10.5732/cjc.014.10123","url":null,"abstract":"<p><p>Considerable progress has been made in the field of cancer immunotherapy in recent years. This has been made possible in large part by the identification of new immune-based cellular targets and the development of novel approaches aimed at stimulating the immune system. The role played by the immunosuppressive microenvironment in the development of tumors has been established. The success of checkpoint-inhibiting antibodies and cancer vaccines has marked the beginning of a new era in cancer treatment. This review highlights the clinically relevant principles of cancer immunology and various immunotherapeutic approaches that have either already entered mainstream oncologic practice or are currently in the process of being evaluated in clinical trials. Furthermore, the current barriers to the development of effective immunotherapies and the potential strategies of overcoming them are also discussed. </p>","PeriodicalId":10034,"journal":{"name":"Chinese Journal of Cancer","volume":"33 9","pages":"445-57"},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/90/cjc-33-09-445.PMC4190434.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32641172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiologic studies of particulate matter and lung cancer.","authors":"Yin-Ge Li,&nbsp;Xiang Gao","doi":"10.5732/cjc.014.10063","DOIUrl":"https://doi.org/10.5732/cjc.014.10063","url":null,"abstract":"<p><p>Particulate matter (PM) plays an important role in air pollution, especially in China. European and American researchers conducted several cohort-based studies to examine the potential relationship between PM and lung cancer and found a positive association between PM and lung cancer mortality. In contrast, the results regarding PM and lung cancer risk remain inconsistent. Most of the previous studies had limitations such as misclassification of PM exposure and residual confounders, diminishing the impact of their findings. In addition, prospective studies on this topic are very limited in Chinese populations. This is an important problem because China has one of the highest concentrations of PM in the world and has had an increased mortality risk due to lung cancer. In this context, more prospective studies in Chinese populations are warranted to investigate the relationship between PM and lung cancer. </p>","PeriodicalId":10034,"journal":{"name":"Chinese Journal of Cancer","volume":"33 8","pages":"376-80"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/30/cjc-33-08-376.PMC4135366.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32494024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical characteristics and treatment outcome of 57 children and adolescents with primary central nervous system germ cell tumors.","authors":"Xiao-Fei Sun,&nbsp;Fei Zhang,&nbsp;Zi-Jun Zhen,&nbsp;Qun-Ying Yang,&nbsp;Yun-Fei Xia,&nbsp;Shao-Xiong Wu,&nbsp;Jia Zhu,&nbsp;Su-Ying Lu,&nbsp;Juan Wang,&nbsp;Fei-Fei Sun,&nbsp;Rui-Qing Cai,&nbsp;Yan Chen,&nbsp;Peng-Fei Li","doi":"10.5732/cjc.013.10112","DOIUrl":"https://doi.org/10.5732/cjc.013.10112","url":null,"abstract":"<p><p>Primary central nervous system germ cell tumors (CNS-GCTs) in children and adolescents have unique clinical features and methods of treatment compared with those in adults. There is little information about Chinese children and adolescents with CNS-GCTs. Therefore, in this study we retrospectively analyzed the clinical features and treatment outcome of Chinese children and adolescents with primary CNS-GCTs. Between January 2002 and December 2012, 57 untreated patients from a single institution were enrolled. They were diagnosed with CNS-GCTs after pathologic or clinical assessment. Of the 57 patients, 41 were males and 16 were females, with a median age of 12.8 years (range, 2.7 to 18.0 years) at diagnosis; 43 (75.4%) had non-germinomatous germ cell tumors (NGGCTs) and 14 (24.6%) had germinomas; 44 (77.2%) had localized disease and 13 (22.8%) had extensive lesions. Fifty-three patients completed the prescribed treatment, of which 18 underwent monotherapy of surgery, radiotherapy, or chemotherapy, and 35 underwent multimodality therapies that included radiotherapy combined with chemotherapy or surgery combined with chemotherapy and/or radiotherapy. PEB (cisplatin, etoposide, and bleomycin) protocol was the major chemotherapy regimen. The median follow-up time was 32.3 months (range, 1.2 to 139 months). Fourteen patients died of relapse or disease progression. The 3-year event-free survival (EFS) and overall survival rates for all patients were 72.2% and 73.8%, respectively. The 3-year EFS was 92.9% for germinomas and 64.8% for NGGCTs (P = 0.064). The 3-year EFS rates for patients with NGGCTs who underwent monotherapy and multimodality therapies were 50.6% and 73.5%, respectively (P = 0.042). Our results indicate that multimodality therapies including chemotherapy plus radiotherapy were better treatment option for children and adolescents with CNS-GCTs. </p>","PeriodicalId":10034,"journal":{"name":"Chinese Journal of Cancer","volume":"33 8","pages":"395-401"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/fa/cjc-33-08-395.PMC4135369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32494027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.","authors":"Wei Zhang,&nbsp;Shi-Yuan Cheng,&nbsp;Li-Fang Hou,&nbsp;Li Yan,&nbsp;Yun-Guang Tong","doi":"10.5732/cjc.014.10110","DOIUrl":"https://doi.org/10.5732/cjc.014.10110","url":null,"abstract":"<p><p>The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on \"Breakthrough Cancer Medicines\" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. </p>","PeriodicalId":10034,"journal":{"name":"Chinese Journal of Cancer","volume":"33 8","pages":"371-5"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/3c/cjc-33-08-371.PMC4135365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32561990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}